Icosavax, Inc. Stock Price, News & Analysis

The FDA has granted Fast Track Designation for Icosavax's IVX-A12, a bivalent VLP vaccine targeting RSV and hMPV. The company completed dosing in the Phase 1 trial, with topline interim results expected in Q2 2023 and a Phase 2 trial initiation planned for H2 2023. As of December 31, 2022, Icosavax reported cash and investments totaling $219.4 million, down from $280.7 million in 2021. In 2022, R&D expenses rose to $65.4 million, up from $38.8 million in 2021, primarily due to increased clinical activities. The net loss for the year was $91.8 million, with a diluted loss per share of $2.31, reflecting rising expenses.

Icosavax, a biopharmaceutical company specializing in vaccine development, will participate in two upcoming investor conferences. The Cowen 43rd Annual Health Care Conference features CEO Adam Simpson on March 7 at 9:10 am ET in Boston. Additionally, Icosavax will present virtually at the Oppenheimer 33rd Annual Healthcare Conference on March 13 at 12:40 pm ET. Investors can access audio webcasts of both events via the company's website, with replays available for 90 days post-event. Icosavax focuses on using its virus-like particle platform to create vaccines for respiratory diseases, including RSV, hMPV, and SARS-CoV-2.

Icosavax, Inc. (Nasdaq: ICVX) announced that the FDA granted Fast Track designation for its IVX-A12 vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults over 60. This designation aims to expedite the development of drugs addressing serious conditions. The vaccine could help mitigate the estimated 177,000 hospitalizations and 14,000 deaths caused by RSV annually in the U.S. Icosavax anticipates topline results from its Phase 1 study in mid-2023, with a Phase 2 trial planned for the second half of 2023.

Icosavax recently reported promising six-month immunogenicity data for its vaccine candidate IVX-121 against RSV, demonstrating sustained immune response. The Phase 1 trial for IVX-A12, a bivalent vaccine for RSV and hMPV, is progressing with topline results expected mid-2023, followed by a Phase 2 initiation in the second half of the year. The company also appointed Jennifer Raymond as Senior Vice President of Technical Operations. With a strong cash position of $222.5 million, Icosavax is well-positioned to fund operations through at least 2024.

Icosavax, focused on vaccines for respiratory diseases, announced promising six-month results from its Phase 1/1b study of IVX-121 against RSV. The data shows sustained neutralizing antibody responses at 64-98% of the levels recorded at day 28, demonstrating the vaccine's durability. IVX-121 remains well tolerated, with no safety concerns reported. Additionally, the company is advancing IVX-A12, a bivalent candidate targeting RSV and hMPV. Icosavax plans to share a 12-month immunogenicity update in mid-2023.

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company focused on developing vaccines for respiratory diseases, announced its participation in the 5th Annual Evercore ISI HealthCONx Conference from November 29 to December 1, 2022. CEO Adam Simpson will engage in a fireside chat on December 1 at 3:55 pm ET. Attendees can access a live audio webcast from the company's Investor Relations webpage, with a replay available for 90 days post-event. Icosavax aims to create multivalent vaccines using its innovative virus-like particle (VLP) technology.